Retatrutide is an investigational compound (Phase 3). Not approved by the FDA, EMA, or MHRA. Not a registered medicine.
Retatrutide — Next-Generation Triple Agonist in Ukraine
The world's first triple GLP-1 + GIP + glucagon agonist — an investigational molecule developed by Eli Lilly. Phase 3 TRIUMPH-1 (topline, May 2026): up to −28.3% weight loss over 80 weeks on the 12 mg dose. Choose your ALLUVI or SYNEDICA dose — research-grade versions from third-party manufacturers.
Price from
15,500 UAH
Choose Your Retatrutide Dose
7
ALLUVI Retatrutide by dose
Individual dose 1.5–12 mg
Buy ALLUVI by dose from 1.5 to 12 mg · step 0.5 mgBuy an ALLUVI Retatrutide dose from 1.5 to 12 mg in 0.5 mg steps. Dose selection with a specialist, delivery across Ukraine.
Retatrutide 12 mg (PEN PEPTIDE)
Next-generation triple agonist · 12 mg · Pre-Mixed Stabilized Pen · PEN PEPTIDE
Retatrutide 12 mg from PEN PEPTIDE — stabilized pen with triple GLP-1/GIP/glucagon agonist. 120 units of 100 mcg each. Optimal for dose escalation phase. MSSPT technology.
💊 Try for 8 000 ₴/mo
Starting dose 2.5 mg · no pen needed · save 20%
Retatrutide 40 mg (SYNEDICA)
Next-generation triple agonist · 40 mg per pen · Synedica Laboratories · Made in Germany
Retatrutide 40 mg from Synedica Laboratories (Germany) — injection pen with triple agonist GLP-1/GIP/glucagon. 4 full doses of 10 mg each (40 mg total), 12 needles 32g 4mm included, instruction manual. Once weekly. Kit lasts approximately 12 weeks on average.
💊 Try for 8 000 ₴/mo
Starting dose 2.5 mg · no pen needed · save 20%
Retatrutide 40 mg (ALLUVI)
Next-generation triple agonist · 40 mg pen · ALLUVI Healthcare
Retatrutide 40 mg by ALLUVI Healthcare — injection pen with triple agonist GLP-1/GIP/glucagon. 4 full doses of 10 mg (40 mg total), 12 needles included, dosing instructions.
Retatrutide 6 mg (PEN PEPTIDE)
Next-generation triple agonist · 6 mg · Pre-Mixed Stabilized Pen · PEN PEPTIDE
Retatrutide 6 mg from PEN PEPTIDE — stabilized pen injector with triple agonist GLP-1/GIP/glucagon. 120 units of 50 mcg each. Starting dose for course initiation. MSSPT technology — stable formula.
Retatrutide 20 mg (PEN PEPTIDE)
Next-generation triple agonist · 20 mg · Pre-Mixed Stabilized Pen · PEN PEPTIDE
Retatrutide 20 mg from PEN PEPTIDE — stabilized pen with triple GLP-1/GIP/glucagon agonist. 200 units of 100 mcg each. Optimal for maintenance dosing. MSSPT technology.
Retatrutide 40 mg (PEN PEPTIDE)
Next-generation triple agonist · 40 mg · Pre-Mixed Stabilized Pen · PEN PEPTIDE
Retatrutide 40 mg by PEN PEPTIDE — stabilized pen injector with triple GLP-1/GIP/glucagon agonist. 200 units of 200 mcg each. Maximum volume for extended treatment course. MSSPT technology.
Buy Retatrutide in Ukraine
Retatrutide is an innovative triple agonist of GLP-1, GIP, and glucagon receptors. The molecule was developed by Eli Lilly; ALLUVI, SYNEDICA and PEN PEPTIDE products are manufactured by third parties and are not Eli Lilly products. Unlike tirzepatide (a dual agonist), retatrutide activates three receptors simultaneously.
Clinical trial results from Phase 3 TRIUMPH-1 (topline, May 2026) showed weight loss of up to −28.3% over 80 weeks on the 12 mg dose — the highest published result in the GLP-1 class. In the extension period (BMI≥35) — up to −30.3% over 104 weeks. Phase 2 (NEJM 2023): up to −24.2% over 48 weeks. The full peer-reviewed Phase 3 publication is pending.
In Ukraine, retatrutide is available under the ALLUVI and SYNEDICA brands (injector pens) with 2-8°C cold chain delivery nationwide. These are third-party products — not the original Eli Lilly drug, which is not yet sold commercially.
DOZA provides a full support cycle — from dose selection with a specialist to results monitoring. Every delivery comes in a certified thermal box with a temperature sensor.
Starting from 15,500 UAH per injector pen. Free delivery and specialist consultation.
Why Choose Retatrutide at DOZA
Triple Mechanism of Action
The only product that simultaneously activates GLP-1, GIP, and glucagon receptors — maximum weight loss efficacy
Up to -28.3% Weight Loss
The Phase 3 TRIUMPH-1 result (topline 2026) on the 12 mg dose over 80 weeks — the highest published result among GLP-1 products
Cold Chain Delivery 2-8°C
Certified thermal box with temperature sensor — guaranteed product quality preservation
24/7 Support
Personal specialist from dose selection to reaching your target weight
ALLUVI & SYNEDICA Brands
Injector pens with precision dosing for convenient self-administration
TRIUMPH Program
Currently undergoing large-scale Phase 3 trials — confirming efficacy and safety
Over 2,147 clients trust DOZA with their weight loss program Learn more about Retatrutide · All DOZA programs
How to Order Retatrutide
Consultation
Free consultation with a DOZA specialist — dose and program selection
Order
Place your order via Telegram with 2-8°C cold chain delivery
Support
Personal progress monitoring and dose adjustment throughout your entire program
Which Retatrutide Dose Is Right for You?
Take a short quiz — a DOZA specialist will select the optimal ALLUVI or SYNEDICA dose for you
Frequently Asked Questions About Retatrutide
Retatrutide is an innovative triple agonist of GLP-1, GIP, and glucagon receptors. The molecule was developed by Eli Lilly and is in Phase 3 (the TRIUMPH program). In TRIUMPH-1 (topline 2026), participants on the 12 mg dose lost an average of 28.3% body weight over 80 weeks. ALLUVI, SYNEDICA and PEN PEPTIDE products are research-grade versions from third-party manufacturers, not Eli Lilly.
Valentyna Tytorenko
Diploma-certified endocrinologist, certified dietitian and nutritionist
Ready to Start with Retatrutide?
Free consultation with a DOZA specialist — we'll select the optimal ALLUVI or SYNEDICA dose for your weight loss program
Get a consultationMessage on Telegram
You May Also Be Interested In
Mounjaro
Dual GLP-1 + GIP agonist by Eli Lilly. Up to -22.5% weight loss over 72 weeks. The gold standard of GLP-1 therapy.
Ozempic
GLP-1 agonist by Novo Nordisk. A proven product with the broadest evidence base for weight loss.
Client Results
Real results and reviews from DOZA clients — before/after photos, video reviews, success stories.
Weight Loss Program
Comprehensive DOZA weight loss program with personal 24/7 specialist support.
DOZA Peptides
Peptide catalog for health, energy, and recovery — MOTS-c, BPC-157, Ipamorelin, and more.
⚠️ Retatrutide is an investigational product currently undergoing Phase 3 clinical trials. Results may vary. Consult a specialist before starting the program. Retatrutide is developed by Eli Lilly and Company. ALLUVI and SYNEDICA are trade names of retatrutide injector pens.